Clinical trial · no report yet · Phase 3

NCT06110663

A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

NCT06110663 ↗
Unknown
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Focused

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

Channel	Found
X threads	4

The trial

ClinicalTrials.gov

Official title: A Phase 3, Randomized, Open-label, Multicenter Study to Assess the Efficacy and Safety of HS-10241 Combined With Almonertinib Versus Pemetrexed Combined With Platinum in Metastatic or Locally Advanced NSCLC With MET Amplification After Failure of the Prior EGFR -TKI Therapy
Phase: Phase 3
Status: Unknown
Conditions: Non-Small Cell Lung Cancer
Interventions: HS-10241+ Almonertinib; Pemetrexed + Cisplatin /Carboplatin
Arms: HS-10241+Almonertinib · Experimental
Pemetrexed + Cisplatin /Carboplatin · Active comparator
Enrollment: 314 (estimated)
Primary outcomes: Progression-free Survival (PFS) evaluated by Independent Review Committee (IRC)
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Start: Dec 30, 2023 (estimated)
Primary completion: Dec 30, 2024 (estimated)
Results posted: No
Registry record: NCT06110663 · updated Nov 1, 2023